Regorafenib, TAS-102, or fruquintinib for metastatic colorectal cancer: any difference in randomized trials?
Qi ZhangQianqian WangXicheng WangJian LiLin ShenZhi PengPublished in: International journal of colorectal disease (2019)
Indirect comparison suggested that the three agents had similar OS but that fruquintinib was superior in terms of PFS compared with that of TAS-102. These three agents had different toxicity profiles.